JPWO2023102407A5 - - Google Patents
Info
- Publication number
- JPWO2023102407A5 JPWO2023102407A5 JP2024532887A JP2024532887A JPWO2023102407A5 JP WO2023102407 A5 JPWO2023102407 A5 JP WO2023102407A5 JP 2024532887 A JP2024532887 A JP 2024532887A JP 2024532887 A JP2024532887 A JP 2024532887A JP WO2023102407 A5 JPWO2023102407 A5 JP WO2023102407A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- omni
- acid substitution
- nuclease variant
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284858P | 2021-12-01 | 2021-12-01 | |
| US63/284,858 | 2021-12-01 | ||
| PCT/US2022/080627 WO2023102407A2 (en) | 2021-12-01 | 2022-11-30 | Engineered high activity omni-79 nuclease variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542883A JP2024542883A (ja) | 2024-11-18 |
| JPWO2023102407A5 true JPWO2023102407A5 (https=) | 2025-12-09 |
| JP2024542883A5 JP2024542883A5 (https=) | 2025-12-09 |
Family
ID=86613099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532887A Pending JP2024542883A (ja) | 2021-12-01 | 2022-11-30 | 改変された忠実度の高いｏｍｎｉ－７９ヌクレアーゼバリアント |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250043260A1 (https=) |
| EP (1) | EP4441210A4 (https=) |
| JP (1) | JP2024542883A (https=) |
| KR (1) | KR20240135608A (https=) |
| CN (1) | CN118647715A (https=) |
| AU (1) | AU2022401869A1 (https=) |
| CA (1) | CA3239753A1 (https=) |
| IL (1) | IL313245A (https=) |
| WO (1) | WO2023102407A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| KR20230142740A (ko) | 2021-02-08 | 2023-10-11 | 에멘도바이오 인코포레이티드 | Omni-103 crispr 뉴클레아제 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4400597A3 (en) * | 2015-10-09 | 2024-10-16 | Monsanto Technology LLC | Novel rna-guided nucleases and uses thereof |
| AU2018240515B2 (en) * | 2017-03-24 | 2024-07-25 | CureVac SE | Nucleic acids encoding CRISPR-associated proteins and uses thereof |
| WO2020223514A2 (en) * | 2019-04-30 | 2020-11-05 | Emendobio Inc. | Novel omni-50 crispr nuclease |
| WO2022119881A1 (en) * | 2020-12-01 | 2022-06-09 | Emendobio Inc. | Differential knockout of a heterozygous allele of lrrk2 |
-
2022
- 2022-11-30 US US18/715,759 patent/US20250043260A1/en active Pending
- 2022-11-30 EP EP22902353.6A patent/EP4441210A4/en active Pending
- 2022-11-30 WO PCT/US2022/080627 patent/WO2023102407A2/en not_active Ceased
- 2022-11-30 IL IL313245A patent/IL313245A/en unknown
- 2022-11-30 JP JP2024532887A patent/JP2024542883A/ja active Pending
- 2022-11-30 KR KR1020247021908A patent/KR20240135608A/ko active Pending
- 2022-11-30 CA CA3239753A patent/CA3239753A1/en active Pending
- 2022-11-30 CN CN202280090501.6A patent/CN118647715A/zh active Pending
- 2022-11-30 AU AU2022401869A patent/AU2022401869A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7610948B2 (ja) | 改変された幹細胞メモリーｔ細胞、その作製方法およびその使用方法 | |
| Golchin et al. | Advancing mesenchymal stem cell therapy with CRISPR/Cas9 for clinical trial studies | |
| JP2024073596A5 (https=) | ||
| US12454685B2 (en) | Variant type V CRISPR/Cas effector polypeptides and methods of use thereof | |
| US20220195416A1 (en) | Rna site-directed editing using artificially constructed rna editing enzymes and related uses | |
| US12385025B2 (en) | Compositions and methods for nucleic acid modifications | |
| US20180237797A1 (en) | Methods for in vitro production of platelets and compositions and uses thereof | |
| CN104046593A (zh) | 一种低免疫原性的人细胞及其制备方法 | |
| CN113302292A (zh) | 遗传修饰细胞的减少和最少的操作制造 | |
| WO2025261231A1 (zh) | 高度靶向人类HLA-A基因的sgRNA、其组合物及应用 | |
| CN111575319A (zh) | 一种高效的crispr rnp和供体dna共位介导的基因插入或替换方法及其应用 | |
| US11359180B2 (en) | Method for producing myocardial cells using synthetic peptide | |
| CN112941106B (zh) | 一种通过foxp1基因编辑和突变延缓间充质干细胞衰老的方法 | |
| US20260015598A1 (en) | Compositions and methods for nucleic acid modifications | |
| JPWO2023102407A5 (https=) | ||
| WO2025261230A1 (zh) | 一种工程化的细胞及其应用 | |
| JPWO2023019263A5 (https=) | ||
| JP2025520547A (ja) | ＣＲＩＳＰＲ活性を調節するための操作Ａｃｒタンパク質 | |
| KR20250005159A (ko) | 안전한 게놈 통합을 위한 신규한 부위 및 그의 사용 방법 | |
| CN109762820B (zh) | 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用 | |
| Brito | Minicircle production and delivery to human mesenchymal stem/stromal cells for angiogenesis stimulation | |
| Becerra et al. | Polyplex system versus nucleofection for human skin cell transfection and effect of internal ribosome entry site sequence | |
| Xiong et al. | Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy | |
| WO2025076084A1 (en) | Engineered nucleases and compositions and methods thereof | |
| Charbord et al. | Bone Marrow Mesenchymal Stem Cells: from Stemness to Stromal Property of Hematopoietic Support |